We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The Advisory Council on the Misuse of Drugs makes recommendations to government on the control of dangerous or otherwise harmful drugs, including classification and scheduling under the Misuse of Drugs Act 1971 and its regul…
This report reviews drug use in ethnic minority groups and outlines recommendations for further data collection.
ACMD Chair: Professor David Wood ACMD Harm Reduction, Treatment and…
May 2026 1. Introduction 1.1 The Advisory Council on the Misuse of Drugs…
Following a 2025 government commission, the ACMD has carried out a review of the use and harms of ketamine.
1. Introduction 1.1. Ketamine is a widely used human and veterinary…
ACMD Chair: Prof David Wood ACMD Ketamine Working Group Chair: Prof Simon…
The Advisory Council on the Misuse of Drugs (ACMD) has today (28 January 2026) published its updated harms assessment of ketamine.
A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.
Safe housing key to tackling homeless drug misuse, says ACMD.
An overview of work carried out by the Advisory Council on the Misuse of Drugs (ACMD) from January 2023 to December 2025.
ACMD review into the use and harms of SSCs and THCA to identify compounds causing harm which are not captured by the current generic definition for cannabinoids.
Report on the long-term prevention of drug use and related harms among young people.
Call for evidence to support ACMD's review of changes to legislation on the use of cannabis-based products for medicinal purposes (CBPMs).
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).